You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/69939
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRocha, Ana T.-
dc.contributor.authorPaiva, Edison F.-
dc.contributor.authorLichtenstein, Arnaldo-
dc.contributor.authorMilani Jr., Rodolfo-
dc.contributor.authorCavalheiro-Filho, Cyrillo-
dc.contributor.authorMaffei, Francisco Humberto de Abreu-
dc.date.accessioned2014-05-27T11:22:37Z-
dc.date.accessioned2016-10-25T18:24:26Z-
dc.date.available2014-05-27T11:22:37Z-
dc.date.available2016-10-25T18:24:26Z-
dc.date.issued2007-10-16-
dc.identifierhttp://dx.doi.org/10.2147/VHRM.S-
dc.identifier.citationVascular Health and Risk Management, v. 3, n. 4, p. 533-553, 2007.-
dc.identifier.issn1176-6344-
dc.identifier.urihttp://hdl.handle.net/11449/69939-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/69939-
dc.description.abstractThe risk for venous thromboembolism (VTE) in medical patients is high, but risk assessment is rarely performed because there is not yet a good method to identify candidates for prophylaxis. Purpose: To perform a systematic review about VTE risk factors (RFs) in hospitalized medical patients and generate recommendations (RECs) for prophylaxis that can be implemented into practice. Data sources: A multidisciplinary group of experts from 12 Brazilian Medical Societies searched MEDLINE, Cochrane, and LILACS. Study selection: Two experts independently classified the evidence for each RF by its scientific quality in a standardized manner. A risk-assessment algorithm was created based on the results of the review. Data synthesis: Several VTE RFs have enough evidence to support RECs for prophylaxis in hospitalized medical patients (eg, increasing age, heart failure, and stroke). Other factors are considered adjuncts of risk (eg, varices, obesity, and infections). According to the algorithm, hospitalized medical patients ≥40 years-old with decreased mobility, and ≥1 RFs should receive chemoprophylaxis with heparin, provided they don't have contraindications. High prophylactic doses of unfractionated heparin or low-molecular-weight-heparin must be administered and maintained for 6-14 days. Conclusions: A multidisciplinary group generated evidence-based RECs and an easy-to-use algorithm to facilitate VTE prophylaxis in medical patients. © 2007 Rocha et al, publisher and licensee Dove Medical Press Ltd.en
dc.format.extent533-553-
dc.language.isoeng-
dc.sourceScopus-
dc.subjectEmbolism and thrombosis-
dc.subjectGuideline-
dc.subjectHeparin-
dc.subjectPrevention and control-
dc.subjectRisk factors-
dc.subjectRisk-assessment-
dc.subjectantineoplastic agent-
dc.subjectdalteparin-
dc.subjectenoxaparin-
dc.subjectestrogen-
dc.subjectfondaparinux-
dc.subjectgestagen-
dc.subjectheparin-
dc.subjecthormone-
dc.subjectlow molecular weight heparin-
dc.subjectnadroparin-
dc.subjectplacebo-
dc.subjectrecombinant erythropoietin-
dc.subjecttamoxifen-
dc.subjectthalidomide-
dc.subjectwarfarin-
dc.subjectacute heart infarction-
dc.subjectage distribution-
dc.subjectcancer-
dc.subjectcancer chemotherapy-
dc.subjectcancer hormone therapy-
dc.subjectcentral venous catheterization-
dc.subjectcerebrovascular accident-
dc.subjectclinical protocol-
dc.subjectclinical trial-
dc.subjectcompression therapy-
dc.subjectcongestive heart failure-
dc.subjectdeep vein thrombosis-
dc.subjectdrug dosage form comparison-
dc.subjectdrug dose comparison-
dc.subjectdrug efficacy-
dc.subjectdrug megadose-
dc.subjectenteritis-
dc.subjectevidence based medicine-
dc.subjecthormonal contraception-
dc.subjecthormone substitution-
dc.subjecthospital patient-
dc.subjecthuman-
dc.subjecthyperhomocysteinemia-
dc.subjectimmobilization-
dc.subjectinfection-
dc.subjectischemic heart disease-
dc.subjectlow drug dose-
dc.subjectlung embolism-
dc.subjectnephrotic syndrome-
dc.subjectobesity-
dc.subjectparesis-
dc.subjectperipheral vascular disease-
dc.subjectpregnancy-
dc.subjectpuerperium-
dc.subjectrespiratory tract disease-
dc.subjectreview-
dc.subjectrheumatic disease-
dc.subjectrheumatoid arthritis-
dc.subjectrisk assessment-
dc.subjectrisk factor-
dc.subjectSwan Ganz catheter-
dc.subjectsystematic review-
dc.subjectsystemic lupus erythematosus-
dc.subjectthrombophilia-
dc.subjectthrombophlebitis-
dc.subjectthrombosis prevention-
dc.subjectvenous thromboembolism-
dc.subjectAlgorithms-
dc.subjectHumans-
dc.subjectRisk Assessment-
dc.subjectThromboembolism-
dc.titleRisk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patientsen
dc.typeoutro-
dc.contributor.institutionUniversidade Federal da Bahia (UFBA)-
dc.contributor.institutionUniversidade de São Paulo (USP)-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.description.affiliationHospital Universitario Professor Edgard Santos da Universidade Federal da Bahia, Rua AlbertoValença, 148, Salvador, Bahia 41810-825-
dc.description.affiliationHospital das Clinicas da Faculdade de Medicina Universidade de Sao Paulo, Sao Paulo-
dc.description.affiliationInstituto do Coracao do Hospital Clinicas da Faculdade de Medicina Universidade de Sao Paulo, Sao Paulo-
dc.description.affiliationFaculdade de Medicina de Botucatu, Botucatu, Sao Paulo-
dc.description.affiliationUnespFaculdade de Medicina de Botucatu, Botucatu, Sao Paulo-
dc.identifier.doi10.2147/VHRM.S-
dc.rights.accessRightsAcesso restrito-
dc.identifier.file2-s2.0-35048898109.pdf-
dc.relation.ispartofVascular Health and Risk Management-
dc.identifier.scopus2-s2.0-35048898109-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.